Fact-checked by Grok 2 weeks ago

Post-transcriptional modification

Post-transcriptional modification refers to the biological alterations of RNA molecules—such as (mRNA), (tRNA), and (rRNA)—after their transcription from DNA but prior to their functional roles, including processes like cleavage, methylation, formation, and splicing that refine RNA structure, stability, and activity. In eukaryotic cells, these modifications are essential for converting the primary RNA transcript, or pre-mRNA, into mature mRNA suitable for . Key steps include the addition of a 7-methylguanosine cap to the 5' end shortly after transcription initiation, which protects the RNA from degradation by exonucleases and facilitates recognition by the during initiation. Splicing follows, where spliceosomes precisely excise non-coding and ligate coding exons, a process guided by conserved sequences like at intron 5' ends and at 3' ends, thereby generating diverse protein isoforms through . At the 3' end, cleavage occurs at a polyadenylation signal (typically AAUAAA), followed by the enzymatic addition of a poly-A tail of approximately 200 residues, which enhances mRNA stability, nuclear export, and translational efficiency. Beyond these structural refinements, post-transcriptional modifications encompass over 170 distinct chemical changes to bases and moieties, influencing dynamically across all kingdoms of life. Prominent examples include N6-methyladenosine (m⁶A), the most abundant internal mRNA modification, which marks sites for accelerated decay via reader proteins like YTHDF2, affecting thousands of transcripts in processes such as differentiation and viral infection responses. Other modifications, such as (Ψ) for structural stabilization and N1-methyladenosine (m¹A) for translational enhancement, respond to cellular stresses and fine-tune RNA-protein interactions, underscoring their role in diseases like cancer when dysregulated. In tRNA and rRNA, modifications like 2'-O-methylation ensure proper folding and decoding accuracy during protein synthesis, highlighting the pervasive impact of these processes on cellular function and adaptability.

Overview and Principles

Definition and Scope

Post-transcriptional modifications encompass a diverse array of chemical and structural alterations to primary RNA transcripts that occur after their synthesis by RNA polymerase but prior to their engagement in cellular functions such as translation or regulation. These changes include site-specific cleavage, nucleotide additions (e.g., capping or polyadenylation), base modifications (e.g., methylation or pseudouridylation), and sequence editing, which collectively refine RNA structure, stability, and interactions. More than 170 distinct modifications have been identified across RNA species, influencing their processing, transport, and functionality without altering the genomic DNA template. The scope of post-transcriptional modifications extends to all major RNA classes—messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), and non-coding RNAs (ncRNAs)—and is observed in organisms from all domains of life, including eukaryotes, prokaryotes, and viruses. In contrast to co-transcriptional modifications, which occur simultaneously with RNA synthesis (e.g., nascent RNA capping in eukaryotes), post-transcriptional events predominantly take place in the nucleus or cytoplasm after transcription termination, enabling fine-tuned regulation tailored to cellular needs. This broad applicability underscores their role in both conserved core processes and specialized adaptations, such as viral RNA evasion of host defenses. Historically, post-transcriptional modifications gained prominence in the with the discovery of pre-mRNA splicing, where non-coding introns are excised from eukaryotic transcripts, as demonstrated in seminal studies on adenovirus . This revelation challenged the one-gene-one-protein paradigm and highlighted RNA processing as a key regulatory layer. The field further expanded in the and early through the emergence of epitranscriptomics, which systematically maps dynamic chemical marks like N⁶-methyladenosine (m⁶A) on mRNA, revealing their and reversibility akin to epigenetic mechanisms. Canonical examples of post-transcriptional modifications include 5′ capping, which adds a 7-methylguanosine cap to protect mRNA and facilitate export; 3′ , which appends a poly(A) tail for ; and splicing, which assembles mature exons. Emerging examples feature (e.g., adenosine-to-inosine ) and events, which modulate efficiency and RNA-protein binding without sequence changes at the DNA level. These modifications are vital for RNA and function, enabling precise control over .

Biological Significance

Post-transcriptional modifications play crucial roles in regulating by facilitating the export of mature RNA transcripts from the to the , where they can be translated into proteins. These modifications, including capping, , and splicing, ensure that only properly processed RNAs are transported through nuclear pores via interactions with export factors like the TREX complex. Without such modifications, RNAs would be retained in the or degraded, preventing efficient . These modifications also enhance stability by protecting transcripts from exonucleolytic degradation; for instance, the 5' and 3' poly(A) tail shield mRNA ends from cellular RNases, extending their and allowing sustained . Additionally, they enable fine-tuned control of , where modifications like N6-methyladenosine (m6A) influence recruitment and scanning, modulating protein synthesis rates in response to cellular needs. , a key post-transcriptional process, generates diverse protein isoforms from a single , vastly expanding the without requiring additional genes. From an evolutionary perspective, post-transcriptional modifications, particularly in eukaryotes alternative splicing has allowed eukaryotic organisms to produce multiple functional proteins from one gene, promoting proteomic diversity and adaptability to environmental stresses. For example, dynamic m6A modifications triage mRNAs into stress granules during cellular stress, sequestering them to halt translation and preserve resources until conditions improve. Defects in these processes underlie various diseases; splicing errors in the SMN1 gene cause spinal muscular atrophy by reducing functional SMN protein levels, while m6A dysregulation promotes oncogenesis in cancers like hepatocellular carcinoma by altering mRNA stability and translation of tumor suppressors. Human mRNAs typically bear multiple such modifications, with more than 170 distinct types identified across the transcriptome, underscoring their pervasive impact. Post-transcriptional modifications integrate into broader regulatory networks, coordinating with microRNAs (miRNAs) and RNA-binding proteins (RBPs) to control mRNA fate. For instance, m6A marks recruit RBPs that either stabilize or destabilize transcripts, while also influencing miRNA-mediated silencing by modulating accessibility, thereby fine-tuning in and . This interplay ensures precise spatiotemporal control, adapting cellular responses to physiological demands.

mRNA Processing

5' Capping

The 5' capping of nascent pre-mRNA is a co-transcriptional modification that occurs early during transcription by (Pol II), typically when the transcript has reached a length of 20-30 from the transcription start site. This timing ensures the cap is added before the nascent is exposed to cellular nucleases, and it is facilitated by the phosphorylation of the C-terminal domain (CTD) of Pol II, which recruits the capping machinery. In eukaryotic cells, particularly in s, the process is catalyzed by a complex involving three enzymatic activities: RNA 5'-triphosphatase, guanylyltransferase, and guanine-N7 methyltransferase. The bifunctional capping enzyme RNGTT integrates the triphosphatase and guanylyltransferase functions, while RNMT performs the methylation step, often in association with Pol II via interactions with the CTD and transcription factors like DSIF.00424-0.pdf) The capping reaction proceeds in three sequential steps on the 5' triphosphate end (pppN) of the nascent pre-mRNA. First, the triphosphatase activity of RNGTT hydrolyzes the γ-phosphate, yielding a diphosphate end (ppN). Second, the guanylyltransferase domain of RNGTT catalyzes the transfer of (GMP) from GTP to the ppN end, forming an unusual 5'-5' triphosphate linkage (GpppN) and releasing . Third, RNMT methylates the N7 position of the added using S-adenosylmethionine as the methyl donor, producing the canonical 0 structure denoted as m^7GpppN. In many metazoan transcripts, an additional 2'-O-methylation on the of the first transcribed (N) is added by CMTR1, forming the 1 structure m^7GpppN_m, which further enhances integrity and recognition. This inverted structure distinguishes eukaryotic mRNAs and is essential for their and . The primary functions of the 5' cap are centered on mRNA stability, nuclear export, and translation efficiency. By masking the 5' triphosphate end, the cap prevents degradation by 5'-3' exoribonucleases such as Xrn1, thereby protecting the nascent transcript during synthesis and maturation. In the nucleus, the cap binds the cap-binding complex (CBC), composed of CBP20 and CBP80, which promotes mRNA export through interactions with export factors like NXF1/NXT1 and also coordinates with splicing machinery for efficient pre-mRNA processing. Upon export to the cytoplasm, the cap is recognized by the eukaryotic initiation factor 4E (eIF4E), which recruits the eIF4F complex to unwind secondary structures and facilitate 5'-end-dependent ribosome scanning for translation initiation. These roles underscore the cap's critical contribution to gene expression, with disruptions in capping linked to diseases such as cancer due to altered mRNA stability and translation.

3' Polyadenylation and Cleavage

In eukaryotic cells, 3' and represent a critical step in mRNA maturation, occurring co-transcriptionally shortly after the polyadenylation site passes the . The process begins with the recognition of specific sequence signals in the pre-mRNA, followed by endonucleolytic and the subsequent addition of a poly(A) tail. The and polyadenylation specificity factor (CPSF) complex plays a central role in identifying the polyadenylation site and executing the , primarily through its CPSF73 subunit, which acts as the endonuclease. Following , poly(A) (PAP) adds approximately 200-250 residues to the newly exposed 3' end in a template-independent manner, forming the poly(A) tail. This tail length is initially regulated by the binding of poly(A)-binding protein nuclear 1 (PABPN1), which stimulates PAP activity until reaching the optimal size, after which further elongation is inhibited. The key signals directing this process include the canonical AAUAAA hexamer motif, located 10-30 upstream of the site, present in about 70-75% of mammalian sites, and a G/U-rich downstream sequence element (DSE) 10-30 downstream, which enhances site recognition. The AAUAAA motif is bound by CPSF subunits such as CPSF30 and WDR33, while the DSE interacts with the (CstF) , particularly CstF64, to stabilize the machinery. These elements ensure precise between the upstream and downstream sequences, with the upstream fragment receiving the poly(A) tail and the downstream fragment being degraded. The discovery of the AAUAAA signal in the mid-1970s through sequencing of globin mRNAs established its conserved role across eukaryotes. The poly(A) tail serves multiple essential functions, including enhancing mRNA stability by protecting the 3' end from exonucleases via interactions with cytoplasmic poly(A)-binding protein (PABPC), facilitating nuclear export through binding to export factors like , and promoting translation efficiency by circularizing the mRNA via PABPC-eIF4G interactions that recruit ribosomes. Variable tail lengths modulate these effects; longer tails (around 200-250 nt initially) correlate with greater stability and translation, while progressive deadenylation shortens the tail to signal decay, thereby regulating mRNA . This process is tightly coordinated with transcription termination, as failure in 3' end processing can lead to read-through transcription. Although most eukaryotic mRNAs undergo , exceptions exist, such as certain non-coding RNAs and replication-dependent mRNAs, which lack poly(A) tails and use alternative 3' end formation mechanisms.

Pre-mRNA Splicing

Pre-mRNA splicing is a critical eukaryotic post-transcriptional modification that removes non-coding introns from primary transcripts and ligates the coding exons to produce (mRNA). This process ensures the accurate expression of protein-coding genes by eliminating intervening sequences that would otherwise disrupt the . Splicing occurs in the and is catalyzed by the , a large ribonucleoprotein (RNP) complex that recognizes specific sequence motifs at intron-exon boundaries. Defects in this machinery can lead to aberrant transcripts, contributing to cellular dysfunction and disease. The splicing mechanism proceeds via two sequential reactions, both of which are phosphoester transfer steps without net input. In the first , the 2'-OH group of an at the within the attacks the 5' splice site, cleaving the upstream and forming a intermediate where the 5' end of the is joined to the . The second involves the 3'-OH of the freed upstream attacking the 3' splice site, ligating the two exons and releasing the for degradation. These reactions are facilitated by the spliceosome's dynamic rearrangements, ensuring precise cleavage and joining.00005-0) Splice site recognition relies on conserved intronic consensus sequences that guide spliceosome assembly. The 5' splice site typically begins with a GU dinucleotide immediately downstream of the exon, while the 3' splice site ends with an AG dinucleotide upstream of the following exon; these motifs are bound by U1 and U2 small nuclear RNPs (snRNPs), respectively. Upstream of the 3' splice site, a branch point sequence containing an (often within a YNYURAC , where Y is and R is ) serves as the for the first ; this site is recognized by U2 snRNP after ATP-dependent unwinding of pre-mRNA secondary structure. Mutations in these signals can impair recognition, leading to splicing errors. The assembles stepwise on the pre-mRNA in an ATP-dependent manner, forming complexes that mature into catalytically active structures. Assembly begins with the E complex, where U1 binds the 5' splice site and splicing factors like SF1 and U2AF associate with the and polypyrimidine tract near the 3' site. This progresses to the A complex with U2 binding the , followed by the pre-catalytic B complex incorporating U4/U6.U5 tri-snRNP. Major rearrangements, driven by RNA helicases (e.g., Prp28, Brr2), activate the spliceosome into the B* complex for the first reaction, then C complex for the second, culminating in exon ligation and disassembly by Prp22 and other factors. The core —U1, U2, U4/U6, and U5—provide RNA elements that base-pair with pre-mRNA and catalyze the reactions through their own structural RNAs.00146-9) Beyond generating functional mRNA, splicing enables evolutionary innovation through mechanisms like shuffling, where recombination between introns in ancestral genes allows modular rearrangement of s to create novel proteins. This process has contributed to the diversity of eukaryotic proteomes by facilitating the assembly of protein domains from disparate genomic regions. Additionally, splicing can produce multiple mRNA isoforms from a single pre-mRNA via splice site choices, expanding proteomic complexity in higher organisms. Errors in pre-mRNA splicing, such as or intron retention, arise from mutations in splice sites, branch points, or spliceosomal components, and account for approximately 15% of pathogenic mutations underlying human genetic diseases. These defects often result in frameshifts, premature termination codons, or inclusion of aberrant sequences, leading to loss-of-function proteins or of transcripts. Examples include from SMN2 exon 7 skipping and certain cancers driven by splicing factor mutations.

Specialized mRNA Processing

Specialized mRNA processing encompasses unique post-transcriptional modifications that deviate from the canonical 5' capping, splicing, and 3' polyadenylation pathway, tailored to the functional needs of specific mRNA classes such as those encoding histones or produced by viruses. These adaptations ensure precise spatiotemporal control, often linking mRNA abundance to cellular states like or infection dynamics. A prominent example is the processing of replication-dependent histone pre-mRNAs, which constitute the majority of histone mRNAs in eukaryotes and lack a poly(A) tail. Instead, their 3' end is formed by endonucleolytic cleavage approximately 5 nucleotides downstream of a conserved stem-loop structure within the pre-mRNA, generating a stable stem-loop that replaces the poly(A) tail. This cleavage is directed by base-pairing between a histone downstream element (HDE) in the pre-mRNA and the U7 small nuclear RNA (snRNA) within the U7 snRNP, which recruits a multiprotein complex including the stem-loop binding protein (SLBP), FLASH, and the endonuclease CPSF-73. The U7 snRNP features a specialized Sm core with Lsm10 and Lsm11 proteins replacing Sm D1 and D2, enabling specific recognition and processing efficiency. SLBP binds directly to the stem-loop immediately after cleavage, playing essential roles in histone mRNA metabolism by facilitating nuclear export via interaction with the export factor 1 (XPO5), enhancing translational efficiency through association, and maintaining stability during the . mRNA levels are tightly regulated to coincide with S-phase ; SLBP expression and activity peak in , promoting accumulation, while at the end of S phase, mRNAs are rapidly degraded to prevent excess production. Degradation initiates with 3' oligouridylation by the TUTase enzyme, followed by binding of the cytoplasmic Lsm1-7 complex to the uridylated 3' end, which accelerates exonucleolytic decay by the exosome and Xrn1. The absence of a poly(A) tail enables this rapid turnover, contrasting with polyadenylated mRNAs, and ensures synthesis is replication-coupled to support assembly without disrupting progression. Viral mRNAs often employ specialized processing to evade defenses and optimize expression in infected cells. Many positive-strand RNA viruses, such as picornaviruses, produce uncapped mRNAs linked at the 5' end to a VPg protein (subsequently removed in some cases), relying on internal ribosome entry sites (IRES) in the (UTR) for cap-independent initiation. These IRES structures mimic canonical initiation signals but recruit the ribosomal subunit directly, bypassing eIF4E-mediated cap recognition and allowing efficient under conditions that inhibit host capped mRNA . Additionally, some viruses generate polycistronic mRNAs encoding multiple proteins from a single transcript, utilizing multiple IRES elements, ribosomal shunting, or programmed frameshifting to produce distinct polypeptides without relying on splicing or internal initiation alone. For instance, viruses like cricket paralysis virus employ IRES-driven polycistronic to express structural and non-structural proteins coordinately during rapid replication cycles. These features enhance viral fitness by decoupling mRNA processing from host machinery constraints, promoting high-level protein synthesis in diverse contexts.

Processing of Non-Coding RNAs

tRNA Maturation

Transfer RNA (tRNA) maturation begins with transcription of precursor tRNA (pre-tRNA) molecules by RNA polymerase III (Pol III) in the nucleus of eukaryotic cells and in archaea and bacteria, producing primary transcripts that include 5' leader and 3' trailer sequences flanking the mature tRNA body. These extensions arise from promoter elements that direct Pol III to initiate and terminate transcription beyond the mature tRNA boundaries, ensuring accurate production of the ~76-nucleotide mature tRNA. This step is universal across all domains of life, reflecting the ancient evolutionary conservation of tRNA biogenesis essential for translation. The primary transcripts undergo end maturation through exonucleolytic and endonucleolytic processing. The 5' leader is removed by RNase P, a ribozyme-protein complex that cleaves precisely at the mature 5' end, while the 3' trailer is trimmed by RNase Z (also known as ELAC2 in eukaryotes), an endonuclease that generates the correct 3' terminus. These enzymes recognize structural features of the pre-tRNA, such as the acceptor stem and T-loop, to ensure site-specific cleavage, a process conserved from to eukaryotes and . In some organisms, additional exonucleases may refine the ends post-cleavage. In eukaryotes and , the prevalence of introns in tRNA genes varies (e.g., ~5% in humans to ~20% in and over 60% in some ), with those present located within the anticodon arm, necessitating splicing for maturation. Unlike spliceosomal splicing of pre-mRNA, tRNA introns are excised by a dedicated tRNA splicing endonuclease (TSEN in eukaryotes; homotetrameric or heterotetrameric endonucleases in archaea) that recognizes the pre-tRNA's tertiary structure or bulge-helix-bulge motifs, respectively, and performs dual cleavages to remove the linear without forming a lariat intermediate. The resulting exon halves, bearing a 5' hydroxyl and 2',3'-cyclic , are then joined by a tRNA (such as Trl1 in or RTCB in humans), healing the ends and restoring the tRNA's cloverleaf structure. This mechanism is absent in most , where tRNA introns, if present, are typically self-splicing group I introns, highlighting domain-specific adaptations in tRNA processing. Maturation concludes with extensive post-transcriptional modifications, with mature tRNAs typically bearing 10-20 modified nucleosides that constitute about 15% of their residues, including base methylations, pseudouridinations, and queuosine formations (detailed further in epitranscriptomic modifications). A universal modification is the enzymatic addition of the 3' sequence by tRNA nucleotidyltransferase (CCA-adding enzyme), which is absent in most pre-tRNAs and essential for subsequent aminoacylation by aminoacyl-tRNA synthetases. These modifications collectively stabilize the tRNA's L-shaped tertiary structure, enhance anticodon-codon base-pairing fidelity during translation, and facilitate efficient amino acid attachment, thereby ensuring accurate protein synthesis across all life forms.

rRNA Processing

In eukaryotes, ribosomal RNA (rRNA) processing begins with the transcription of a large 45S pre-rRNA precursor by in the . This primary transcript undergoes a series of sequential endonucleolytic cleavages to generate the mature 18S, 5.8S, and 28S rRNAs that form the core of the and 60S ribosomal subunits. Key processing steps include initial cleavages at sites A0, , and A2 to separate the 18S rRNA precursor, followed by further maturation in the internal transcribed spacers (ITS1 and ITS2); for instance, the endonuclease Las1, in complex with Grc3 and Rat1, catalyzes the critical C2 cleavage in ITS2 to yield the 5.8S and 28S precursors. These cleavages ensure precise separation of the functional rRNAs from non-coding spacer sequences, with processing pathways varying slightly between species but converging on the production of mature forms essential for assembly. Assembly of ribosomal subunits occurs concurrently in the , where the pre-rRNAs associate with over 150 trans-acting factors, including small nucleolar ribonucleoproteins (snoRNPs) that guide site-specific 2'-O-methylations and pseudouridylations to stabilize the rRNA structure. The pre-ribosomal particle forms first, incorporating the 18S rRNA precursor, before maturing into separate pre-40S and pre-60S particles that are exported to the for final into functional 80S ribosomes. In prokaryotes, rRNA processing differs markedly, as the 16S, 23S, and 5S rRNAs are transcribed as separate precursors or polycistronic units, with minimal cleavages by RNases like RNase III to form the 30S and 50S subunits. These subunits then assemble independently in the , lacking a dedicated nucleolar compartment. Mature rRNAs constitute the structural and catalytic core of , facilitating protein synthesis, and account for approximately 80% of total cellular due to the high demand for ribosome production. mechanisms, primarily mediated by the RNA exosome complex—a multi-subunit 3'-5' exoribonuclease—degrade aberrant pre-rRNA fragments and faulty intermediates generated during processing, preventing their incorporation into dysfunctional . For example, the exosome targets unprocessed spacers and defective pre-rRNAs, ensuring efficient biogenesis and cellular .

Other Non-Coding RNAs

Small nuclear RNAs (snRNAs) are essential non-coding RNAs involved in pre-mRNA splicing as components of the . Most snRNAs, such as U1, , U4, and U5, are transcribed by (Pol II), while U6 is transcribed by (Pol III). Following transcription, Pol II-transcribed snRNAs receive a 7-methylguanosine (m7G) cap at the 5' end, which is subsequently hypermethylated to a 2,2,7-trimethylguanosine (TMG) cap by the trimethylguanosine synthase (TGS1). This TMG cap facilitates nuclear retention and stability. Additionally, snRNAs bind to proteins at their 3' end in the , forming the Sm core that is crucial for nuclear import via the mRNA export factor PHAX and subsequent spliceosomal assembly. These modifications ensure the maturation of snRNPs for their role in facilitating splicing reactions. Small nucleolar RNAs (snoRNAs) guide post-transcriptional modifications on ribosomal RNAs and other targets, primarily within the . They are classified into box C/D snoRNAs, which contain conserved C (RUGAUGA) and D (CUGA) motifs forming a kink-turn , and box H/ACA snoRNAs, characterized by hairpin-hinge-hairpin-tail architecture with H (ANANNA) and ACA motifs. Approximately 90% of human snoRNAs are encoded within introns of host genes and are through splicing-dependent or independent pathways. In the splicing-dependent route, snoRNAs are excised from debranched lariat introns via exonucleolytic trimming by enzymes like XRN2 and the exosome; splicing-independent involves endonucleolytic cleavage by RNase III family members such as RNT1. Box C/D snoRNAs assemble with core proteins (e.g., FBL, NOP56, NOP58, SNU13) to form snoRNPs that direct 2'-O-methylation on rRNA, while H/ACA snoRNAs associate with DKC1 and other proteins to catalyze pseudouridylation. MicroRNAs (miRNAs) are short non-coding RNAs (~22 nucleotides) that regulate through post-transcriptional silencing. In the canonical biogenesis pathway, primary miRNAs (pri-miRNAs) are transcribed by Pol II as long hairpin-containing transcripts. These are cleaved in the by the Drosha-DGCR8 microprocessor complex into precursor miRNAs (pre-miRNAs), approximately 70-nucleotide hairpins. Pre-miRNAs are exported to the cytoplasm by Exportin-5/RanGTP, where , in complex with TRBP, performs a second cleavage to generate the mature miRNA duplex. The duplex is loaded into proteins within the (RISC), where one strand (the guide miRNA) directs target mRNA recognition, leading to translational repression or degradation. These non-coding RNAs collectively contribute to key regulatory processes: snRNAs enable accurate pre-mRNA splicing by forming the , snoRNAs ensure proper rRNA maturation for through guided modifications, and miRNAs mediate to fine-tune transcript levels.

RNA Editing

Adenosine-to-Inosine Editing

Adenosine-to-inosine (A-to-I) RNA editing is a post-transcriptional modification in which adenosine residues in RNA are deaminated to inosine by adenosine deaminases acting on RNA (ADAR) enzymes. This hydrolytic deamination reaction involves the removal of an amine group from adenosine, converting it to inosine, which is recognized as guanosine by the translational machinery and splicing factors. The process specifically targets double-stranded RNA (dsRNA) structures, with ADAR enzymes—primarily ADAR1, ADAR2, and ADAR3—catalyzing the reaction through their deaminase domains, while dsRNA-binding domains ensure substrate specificity. ADAR1 and ADAR2 are catalytically active, whereas ADAR3 lacks deaminase activity and may act as a regulator. In the human transcriptome, A-to-I editing sites are abundant, estimated to exceed 100 million, with the vast majority occurring within Alu repetitive elements, particularly in the 3' untranslated regions (UTRs) of mRNAs. These Alu-derived inverted repeats form dsRNA structures that serve as preferred substrates for enzymes, leading to clustered editing events known as hyper-. While is widespread in non-coding regions, a smaller occurs in coding sequences and introns, influencing RNA processing and function. Functionally, A-to-I editing diversifies the by altering RNA secondary structure, splicing patterns, (miRNA) targeting, and efficiency. For instance, editing can introduce exon-skipping or alternative splice usage by modifying splice site recognition, as seen in the editing of transcripts by ADAR2. It also disrupts miRNA-mRNA interactions in 3' UTRs, thereby regulating post-transcriptionally. Additionally, extensive hyper-editing by ADAR1 prevents the activation of innate immune sensors like and PKR by masking viral dsRNA as self, providing an antiviral defense mechanism. Dysregulation of A-to-I editing is implicated in various diseases, particularly neurological disorders and cancers. In , altered editing levels of transcripts, such as those encoding GluA2 subunits, disrupt neuronal excitability and synaptic transmission. In cancer, upregulated ADAR1 activity promotes immune evasion by suppressing dsRNA-triggered responses, facilitating tumor progression in malignancies like and .

Cytidine-to-Uridine Editing

Cytidine-to- (C-to-U) editing is a post-transcriptional modification in which bases within transcripts are deaminated to by members of the family of enzymes, primarily APOBEC1 in mammals. This process alters the sequence, effectively changing a (C) to a (T) in the corresponding protein-coding sense, and is mediated through a multi-protein editosome complex. The core mechanism involves APOBEC1, an RNA-specific cytidine deaminase, which catalyzes the hydrolytic deamination of cytidine to uridine at specific motifs, typically featuring a downstream AU-rich element and an upstream enhancer sequence. APOBEC1 alone lacks sufficient substrate specificity for mRNA editing and requires cofactors such as APOBEC1 complementation factor (ACF), which binds RNA and positions the target cytidine in the enzyme's active site via its RNA recognition motifs. This cofactor-dependent assembly ensures efficient, site-selective editing, with ACF also facilitating nuclear-cytoplasmic shuttling of the complex. A classic example of C-to-U editing occurs in the (APOB) mRNA, where APOBEC1 deaminates a specific at position 6666 in the , introducing a premature (CAA to UAA). This recoding event produces a truncated protein, APOB48, essential for assembly and absorption, in contrast to the full-length APOB100 synthesized in the liver. Beyond APOB, C-to-U editing is widespread across the , particularly in 3' untranslated regions (3' UTRs) of numerous mRNAs, with over 50 validated targets in mice showing editing efficiencies from 30% to 85%. Functionally, C-to-U editing enables protein isoform diversity through recoding, as exemplified by the APOB switch, which supports tissue-specific metabolic adaptations. It also contributes to innate immunity by targeting viral RNAs; APOBEC1 and related family members deaminate cytidines in viral transcripts, introducing mutations that disrupt replication and enhance antiviral responses. Regulation of C-to-U editing is highly tissue-specific, with APOBEC1 expression and cofactor availability elevated in the to drive APOB editing, while other tissues like liver show minimal activity. Dysregulation, such as ectopic APOBEC1 expression, can lead to aberrant editing and off-target effects, including increased somatic mutations implicated in B-cell non-Hodgkin lymphomas and leukemias. Notably, while APOBEC enzymes primarily act on , they share structural similarities that enable occasional DNA editing, though RNA remains the predominant substrate for APOBEC1.

Other Editing Mechanisms

Beyond the canonical adenosine-to-inosine and cytidine-to-uridine deaminations, other RNA editing mechanisms encompass diverse processes that alter sequences through splicing, insertion, or engineered interventions, often exhibiting organism-specific adaptations. In trypanosomes, trans-splicing serves as a key editing mechanism, where a short spliced leader () sequence from a distinct donor is covalently joined to the 5' end of pre-mRNA transcripts derived from polycistronic precursors, generating mature monocistronic mRNAs essential for protein expression. This process, mediated by a spliceosomal machinery analogous to cis-splicing but involving intermolecular ligation, ensures the addition of a common 5' cap structure and is universal for all trypanosome mRNAs, facilitating rapid to host environments in parasitic life cycles. A related in trypanosomes involves extensive U-insertion and U-deletion , which dramatically reshapes mitochondrial mRNA sequences through guide RNAs that direct enzymatic cycles of , addition or removal of uridines, and religation, often increasing transcript length by up to 50% or more to create functional open reading frames. This site-specific , catalyzed by a multiprotein including endonucleases, uridylyl transferases, and RNA like REL1, is vital for mitochondrial and survival, with inhibitors of the ligase demonstrating lethal effects . In , while C-to-U predominates in organelles, rarer U-to-C conversions occur in certain lineages such as mosses and ferns, potentially restoring conserved codons or adapting to environmental stresses, though these events are less frequent and mechanistically enigmatic compared to deaminations. Emerging engineered approaches have expanded RNA editing capabilities, notably through CRISPR-Cas13-based systems like (RNA Editing for Specific C-to-U Exchange), developed in 2019, which fuses a deactivated Cas13b with a deaminase (such as APOBEC1 variant) and a uridine glycosylase inhibitor to enable programmable C-to-U edits in mammalian transcripts without DNA alterations. Similarly, earlier REPAIR systems (introduced in 2017) target A-to-I changes, but RESCUE's multiplexed potential—editing multiple sites simultaneously—highlights therapeutic applications, such as correcting disease-associated mutations in transcripts for or models, achieving up to 20-30% efficiency in cell lines. Physical editing via RNA ligation has also been harnessed, as in ribozyme-mediated trans-ligation of cleaved mRNAs to produce full-length proteins scarlessly, offering precise sequence fusions for . As of 2025, RNA editing therapeutics have advanced to early clinical trials, with ADAR-based platforms demonstrating the first therapeutic RNA editing in humans for conditions like (e.g., Wave Life Sciences' RestorAATion trial), and additional candidates targeting liver, CNS, and genetic diseases entering trials by companies such as ProQR, Korro Bio, and AIRNA, underscoring the modality's growing clinical potential. These mechanisms underscore species-specific roles, such as antigenic variation in trypanosomes for immune evasion or codon optimization in for metabolic efficiency, while their therapeutic promise lies in transient, reversible edits avoiding permanent genomic changes. However, such non-canonical editing remains rare in mammals, comprising only about 1-5% of total editing events, often limited by off-target effects or low endogenous frequencies outside stress responses like hypoxia-induced APOBEC3 activity.

Epitranscriptomic Modifications

N6-Methyladenosine (m6A)

N6-Methyladenosine (m6A) is the most prevalent and conserved internal post-transcriptional modification in eukaryotic (mRNA), occurring on approximately 0.1–0.4% of all adenosines and accounting for over 50% of known methylation events. First discovered in 1974 through analysis of poly(A) RNA from Novikoff hepatoma cells, where it was identified as a major methylated , m6A has since been recognized as a dynamic epitranscriptomic mark influencing across diverse organisms. Early studies in the established its presence in viral, bacterial, and eukaryotic RNAs, but renewed interest in the revealed its reversibility and regulatory roles, transforming it from a static feature into a tunable layer of post-transcriptional control. The installation of m6A occurs co-transcriptionally in the , primarily catalyzed by the core methyltransferase complex formed by METTL3 and METTL14, which uses () as the methyl donor to target the N6 position of within the consensus motif DRACH (D = A/G/U; R = A/G; H = A/C/U). METTL3 serves as the catalytically active subunit, binding and facilitating methyl transfer, while METTL14 acts as a structural adaptor that enhances RNA substrate recognition and stabilizes the complex, enabling efficient at a subset of potential sites.00496-8.pdf) This process is further modulated by accessory proteins like WTAP, which recruits the complex to specific regions near transcription start sites. Once installed, m6A is recognized by reader proteins, predominantly the YTH domain family—including cytoplasmic YTHDF1, YTHDF2, and YTHDF3, and nuclear YTHDC1 and YTHDC2—which bind the modified base via their conserved YTH domains to mediate downstream effects on fate. The modification's reversibility is ensured by erasers such as FTO and ALKBH5, oxidative demethylases that remove the using α-ketoglutarate and (II); FTO, the first identified , was characterized in 2011 as localizing to nuclear speckles to counteract m6A accumulation. Genome-wide mapping has shown that m6A is non-randomly distributed, with peaks enriched near stop codons (accounting for about 25% of sites) and in 3' untranslated regions (UTRs, comprising roughly 40% of modifications), while coding sequences harbor the majority (around 50%) but at lower density.00536-3) This localization pattern, observed across , , and other mammalian transcriptomes, positions m6A to interface with key regulatory elements like binding sites in 3' UTRs, influencing post-transcriptional networks. The modification's dynamics vary temporally and spatially; for instance, levels fluctuate during embryonic and , with higher abundance in stem cells and oocytes compared to differentiated tissues. m6A exerts multifaceted regulatory functions on mRNA metabolism, primarily through reader-mediated recruitment of processing factors. In splicing, nuclear YTHDC1 binds m6A sites to promote inclusion by interacting with splicing machinery, as demonstrated in mammalian cells where its depletion alters patterns.00894-5) For nuclear export, m6A facilitates mRNA release from the via YTHDC1 coordination with the complex, enhancing trafficking efficiency. Cytoplasmic readers like YTHDF2 accelerate mRNA by localizing marked transcripts to decay sites, reducing stability, while YTHDF1 boosts by associating with initiation factors such as eIF3 on polysomes. These effects are particularly pronounced during , where m6A dynamics in oocytes and embryos regulate maternal-to-zygotic transition and cell fate decisions, as seen in Xenopus laevis where stage-specific m6A profiles correlate with shifts. Dysregulation of the m6A machinery contributes to diseases, notably through FTO variants linked to ; genome-wide association studies have identified FTO polymorphisms as the strongest genetic risk factors for common , with FTO-mediated demethylation altering mRNA stability of metabolic regulators like IRX3 and IRX5. In cancer, aberrant METTL3 activity promotes tumorigenesis by enhancing translation of oncogenes such as , underscoring m6A's therapeutic potential.

Pseudouridylation and Other Base Modifications

Pseudouridylation is a post-transcriptional of to (Ψ), the most abundant modification, occurring in rRNA, tRNA, snRNA, and mRNA. This modification is catalyzed by synthases ( enzymes), such as Pus1 in and its human homologs, which recognize specific sequences or structures to rearrange the uracil base via a C-C , enhancing base stacking and RNA stability. Some pseudouridylation events are standalone, guided solely by enzymes, while others in rRNA and snRNA are directed by box H/ACA small nucleolar RNAs (snoRNAs) that base-pair with target RNAs to recruit the core complex including dyskerin (DKC1). The structural impacts of pseudouridylation improve RNA folding by increasing rigidity and hydrogen bonding potential without altering base-pairing specificity, which is critical for tRNA anticodon loop function and rRNA biogenesis in . In tRNA, Ψ modifications stabilize the molecule against nucleases, while in rRNA, they ensure proper 18S and 28S maturation; disruptions in activity lead to defects in translation efficiency and ribosome . Pseudouridylation, like other epitranscriptomic modifications such as N6-methyladenosine (m6A), can exhibit dynamic regulation, particularly in mRNA, while providing structural reinforcement. Other base modifications include (m5C), installed by RNA methyltransferases like NSUN2, which transfers a to the C5 position of , predominantly in tRNA and rRNA but also in mRNA. NSUN2-mediated m5C enhances mRNA from the and by promoting interactions with export factors like ALYREF, and it stabilizes tRNA against during . N1-methyladenosine (m1A), another event, occurs mainly at position 58 in tRNA and is catalyzed by TRMT6/TRMT61A complexes, positively charging the to restrict base pairing and improve tRNA folding and initiator tRNA function in translation initiation.00627-X) These modifications collectively bolster RNA structural integrity and functional roles in non-coding RNAs; for instance, m5C in rRNA aids , while m1A in tRNA supports cellular stress responses and protein synthesis fidelity. Advances in detection since the have enabled precise mapping, with providing quantitative analysis of Ψ via stable isotope labeling and chemical derivatization, and sequencing methods like Ψ-seq or CMC-based approaches achieving base-resolution identification in total RNA. Nanopore direct RNA sequencing has further improved single-molecule detection of Ψ by signal deviations, overcoming earlier limitations in low-abundance transcript analysis.

RNA Backbone Alterations

RNA backbone alterations refer to chemical modifications that target the phosphodiester backbone or the sugar moiety of RNA, enhancing and functional specificity without altering the base sequence. The most prevalent natural modification in this category is 2'-O-methylation (Nm), where a is added to the 2'-hydroxyl position of the sugar, catalyzed by the methyltransferase fibrillarin (FBL) in complex with box C/D small nucleolar ribonucleoproteins (snoRNPs). These snoRNPs guide the modification to specific sites through base-pairing with target RNAs, ensuring precise deposition during RNA maturation. In human cells, 2'-O-methylation is abundant in (rRNA), with approximately 120 sites identified across the 18S, 5.8S, and 28S rRNAs, and it is also common in small RNAs (snRNAs) involved in splicing. This modification increases RNA's resistance to by sterically hindering enzymatic cleavage and stabilizes the helix through enhanced base stacking and reduced flexibility. Furthermore, facilitates specific protein binding, such as ribosomal proteins to rRNA, which is essential for efficient and assembly in the . Beyond natural modifications, synthetic phosphorothioate () analogs replace one non-bridging oxygen in the phosphodiester backbone with , conferring high resistance and improved cellular uptake in therapeutic RNAs like antisense and siRNAs. These backbone changes mimic natural protective roles but are engineered for drug stability, as seen in FDA-approved therapies for . Recent studies highlight the immunological significance of 2'-O-methylation, where its absence on viral or synthetic RNAs serves as a "non-self" signal, triggering recognition by the cytosolic sensor and subsequent type I responses. For instance, unmethylated RNAs activate more potently than methylated counterparts, underscoring Nm's role in distinguishing host from pathogen-derived nucleic acids during innate immunity. These alterations often coordinate with epitranscriptomic base modifications to fine-tune RNA recognition, though backbone changes primarily confer physical protection.

References

  1. [1]
    RNA Processing, Post-Transcriptional - MeSH - NCBI
    ### Summary of RNA Processing, Post-Transcriptional (MeSH Definition)
  2. [2]
    RNA Processing in Eukaryotes - OpenEd CUNY
    The process of removing introns and reconnecting exons is called splicing (Figure). Introns are removed and degraded while the pre-mRNA is still in the nucleus.Missing: post- | Show results with:post-
  3. [3]
    The emerging biology of RNA post-transcriptional modifications - PMC
    Dec 12, 2016 · It has been known for decades that RNA from all kingdoms of life can be post-transcriptionally modified with over 100 chemical moieties.Missing: definition | Show results with:definition
  4. [4]
    Going global: the new era of mapping modifications in RNA - PMC
    Jun 1, 2016 · The post-transcriptional modification of RNA by the addition of one or more chemical groups has been known for over 50 years.
  5. [5]
    The emerging role of RNA modifications in the regulation of mRNA ...
    Mar 24, 2020 · These RNA modifications can affect a variety of molecular processes, such as transcription, pre-mRNA splicing, RNA export, mRNA translation, and ...
  6. [6]
    Mechanisms of RNA export and nuclear retention - Khan
    Aug 17, 2022 · RNA export involves splicing-dependent TREX recruitment and sequence-dependent mechanisms. Nuclear retention of some RNAs, like lncRNAs, is ...EXPORTIN-DEPENDENT... · EXPORT OF lncRNAs · RNA MODIFICATION AND...
  7. [7]
    Post-transcriptional gene regulation by mRNA modifications - NIH
    RNA from all living organisms can be post-transcriptionally modified by a collection of more than 100 distinct chemical modifications. Among these modifications ...<|control11|><|separator|>
  8. [8]
    Alternative splicing and protein structure evolution - Oxford Academic
    The effects of alternative splicing on the function of a single protein range from changes in substrate or interaction partner specificity to the regulation of ...
  9. [9]
    Alternative splicing and the evolution of phenotypic novelty - Journals
    Feb 5, 2017 · Novel alternative splicing events allow single-copy gene A to produce two protein isoforms, each optimized for expression in a specific tissue.
  10. [10]
    Dynamic m6A methylation facilitates mRNA triaging to stress granules
    Jul 3, 2018 · This methylation pattern provides a selective mechanism for triaging mRNAs from the translatable pool to stress-induced stress granules.
  11. [11]
    A single nucleotide in the SMN gene regulates splicing and ... - PNAS
    A critical question is why only the homozygous loss of SMN1, and not SMN2, results in spinal muscular atrophy (SMA).Results · Alternative Splicing Of Smn... · Transient Expression Of...
  12. [12]
    m6A Modification in Coding and Non-coding RNAs: Roles and ...
    Mar 16, 2020 · m 6 A affects the fate of the modified RNA molecules and plays important roles in almost all vital bioprocesses, including cancer development.
  13. [13]
    Modeling the combined effect of RNA-binding proteins and ...
    Recent studies show that RNA-binding proteins (RBPs) and microRNAs (miRNAs) function in coordination with each other to control post-transcriptional regulation ...
  14. [14]
    Structure and Function of Pre-mRNA 5′-End Capping Quality ...
    5′-end capping occurs very early during Pol II transcription, typically after the synthesis of ∼20 nucleotides of the pre-mRNA. Capping has been linked to ...
  15. [15]
    Structures of co-transcriptional RNA capping enzymes on paused ...
    May 30, 2024 · The 5′-end capping of nascent pre-mRNA represents the initial step in RNA processing, with evidence demonstrating that guanosine addition ...
  16. [16]
    5′-Capping enzymes are targeted to pre-mRNA by binding to the ...
    The capping reaction is catalyzed by three enzymes: (1) RNA triphosphatase, which removes the terminal phosphate; (2) RNA guanylyltransferase, which transfers ...
  17. [17]
    Human mRNA capping enzyme (RNGTT) and cap ... - PubMed
    Human mRNA capping enzyme (RNGTT) and cap methyltransferase (RNMT) map to 6q16 and 18p11.22-p11.23, respectively.
  18. [18]
    RNGTT - mRNA-capping enzyme - Homo sapiens (Human) - UniProt
    Aug 1, 1998 · Bifunctional mRNA-capping enzyme exhibiting RNA 5'-triphosphate monophosphatase activity in the N-terminal part and mRNA guanylyltransferase activity in the C- ...
  19. [19]
    Structural insights into human co-transcriptional capping
    Jul 20, 2023 · The human mRNA capping enzyme, RNGTT, first docks to the Pol II stalk to position its triphosphatase domain near the RNA exit site. The capping ...
  20. [20]
    RNMT-dependent RNA cap methylation in health and disease
    Sep 9, 2025 · The mechanisms by which RNMT is regulated by signalling pathways, co-factors and other enzymes are explored. The m7G cap protects RNA pol II- ...
  21. [21]
    Structural basis for m7G recognition and 2′-O-methyl ... - PNAS
    Jan 5, 2016 · This paper provides structural and mechanistic insights into the roles of the m7G cap and 2′-O-methylation in RIG-I evasion.
  22. [22]
    Interplay of mRNA capping and transcription machineries
    Jan 24, 2020 · The mRNA capping machinery has three basic activities: RNA 5′-triphosphatase (RT), guanylyltransferase (GT), and RNA guanine-N7 ...Introduction · Capping Machinery... · Capping Apparatus Has An...
  23. [23]
    The Cap-Binding Complex CBC and the Eukaryotic Translation ...
    It enables the engagement of specific cap-binding factors such as CBC and eIF4E and, furthermore, it protects RNAs from degradation by 5′exonucleases [31,32].2. Rna Maturation, Nuclear... · 2.2. Rna Splicing · 3. Models For Rna Maturation...<|control11|><|separator|>
  24. [24]
    Advances in understanding and targeting eIF4E activity
    The m7G cap is a crucial 5'-epi-transcriptomic modification in eukaryotic mRNA that provides stability and protection against degradation [12,13] and serves as ...
  25. [25]
    Cleavage and polyadenylation: Ending the message expands gene ...
    Cleavage and polyadenylation (pA) is a fundamental step that is required for the maturation of primary protein encoding transcripts into functional mRNAs.
  26. [26]
  27. [27]
    Roles of mRNA poly(A) tails in regulation of eukaryotic gene ...
    Mar 13, 2023 · The poly(A) tail contributes to both the translational status and stability of mRNAs, and it functions as a master regulator of gene expression ...
  28. [28]
    Ending the message: poly(A) signals then and now - PMC
    The central sequence motif AAUAAA was identified in the mid-1970s and subsequently shown to require flanking, auxiliary elements for both 3′-end cleavage and ...
  29. [29]
    Genetic interactions between the 5' and 3' splice site consensus ...
    The YAG/ consensus sequence at the 3' end of introns (the slash indicates the location of the 3' splice site) is essential for catalysis of the second step ...
  30. [30]
    Structural basis of catalytic activation in human splicing - Nature
    May 10, 2023 · Pre-mRNA splicing occurs in two transesterification reactions on the spliceosome, the sequential assembly and remodelling of which are ...
  31. [31]
    Exon shuffling by recombination between self-splicing introns of ...
    Aug 17, 1989 · THE organization of genes into exons separated by introns may permit rapid evolution of protein-coding sequences by exon shuffling1.
  32. [32]
    Missed threads. The impact of pre-mRNA splicing defects on clinical ...
    Although the frequency of splicing mutations varies considerably between individual genes, it is likely that approximately 15% of pathogenic mutations cause ...Missing: percentage | Show results with:percentage
  33. [33]
    Metabolism and regulation of canonical histone mRNAs
    Recent evidence suggests that the specialized 3′ end of replication-dependent histone mRNAs originated early in the evolution of eukaryotes but was completely ...
  34. [34]
    Formation of the 3' end of histone mRNA: Getting closer to the end
    This review summarizes what is currently known about 3' end processing of histone pre-mRNAs and emphasizes important breakthroughs that have been made in ...
  35. [35]
    Unique Sm core structure of U7 snRNPs: assembly by a specialized ...
    The U7 snRNP involved in histone RNA 3′ processing contains a structurally similar but biochemically unique Sm core in which two of these proteins, Sm D1 and D2 ...
  36. [36]
    Stem-loop binding protein, the protein that binds the 3 ... - PubMed
    A 31-kDa stem-loop binding protein (SLBP) binds the 3' end of histone mRNA. The SLBP is necessary for pre-mRNA processing and accompanies the histone mRNA ...Missing: Lsm complex seminal paper
  37. [37]
    Birth and Death of Histone mRNAs - PMC - PubMed Central
    Histone mRNAs are rapidly degraded when DNA replication is inhibited by a 3′ to 5′ pathway that requires extensive uridylation of mRNA decay intermediates.
  38. [38]
    Conventional and unconventional mechanisms for capping viral ...
    Here, we review the strategies used by viruses of eukaryotic cells to produce functional mRNA 5′-caps and escape innate immunity.<|control11|><|separator|>
  39. [39]
    Viral subversion of the host protein synthesis machinery - PMC - NIH
    This Review discusses the diverse strategies that viruses use to subvert host protein synthesis functions and regulate mRNA translation in infected cells.
  40. [40]
    Signaling to and from the RNA Polymerase III Transcription and ...
    Each nascent tRNA transcript is subject to multiple processing steps: 5′ leader and 3′ trailer extensions are cleaved by RNase P and RNase Z respectively, ...
  41. [41]
    Transfer RNA Post-Transcriptional Processing, Turnover, and ... - NIH
    The addition of CCA nucleotides to mature 3′ tRNA termini is prerequisite for tRNA aminoacylation and therefore required for tRNA biogenesis and function.<|control11|><|separator|>
  42. [42]
    3′ processing of eukaryotic precursor tRNAs - PMC - NIH
    The universal steps in tRNA biogenesis are transcription, 5′ and 3′ end processing, the common nucleotide modifications, addition of CCA to the processed 3′ end ...
  43. [43]
    Repairing tRNA termini: News from the 3' end - PMC - NIH
    The removal of transcriptional 5′ and 3′ extensions is an essential step in tRNA biogenesis. In some bacteria, tRNA 5′- and 3′-end maturation require no further ...Introduction · ``regular'' Trna 5′ And... · Trna 5′-End Maturation
  44. [44]
    New insights into RNA processing by the eukaryotic tRNA splicing ...
    In archaeal and eukaryotic tRNA splicing, a tRNA splicing endonuclease (TSEN) separates the exons from the intron, and a tRNA ligase subsequently joins the ...
  45. [45]
    CCA Addition to tRNA: Implications for tRNA Quality Control - PMC
    Summary. The CCA sequence is conserved at the 3' end of all mature tRNA molecules to function as the site of amino acid attachment.Missing: III | Show results with:III
  46. [46]
    Modifications and functional genomics of human transfer RNA - Nature
    Feb 20, 2018 · The nuclear-encoded tRNAs are very extensively modified, containing an average of 13 modifications per molecule.
  47. [47]
    An overview of pre-ribosomal RNA processing in eukaryotes - PMC
    CONCLUSION. This overview of pre-rRNA processing shows that despite a deep understanding of these mechanisms, basic elements are still missing in the blueprint ...
  48. [48]
    Pre-Ribosomal RNA Processing in Human Cells - MDPI
    In the main pre-rRNA processing pathway observed in mammalian cells, cleavage of the 45S pre-rRNA at site 2 separates the 30S pre-rRNA, precursor to the 18S ...
  49. [49]
    Grc3 programs the essential endoribonuclease Las1 for ... - PNAS
    Jun 26, 2017 · Las1 is a recently discovered endoribonuclease that collaborates with Grc3–Rat1–Rai1 to process precursor ribosomal RNA (rRNA), ...
  50. [50]
    snoRNPs: Functions in Ribosome Biogenesis - PubMed - NIH
    May 18, 2020 · As suggested by their name, they localize to the nucleolus, the site of ribosome biogenesis. There, they facilitate multiple roles in ribosomes ...
  51. [51]
    The Lifecycle of Ribosomal RNA in Bacteria - NCBI
    In bacteria the translationally active 70S ribosome is formed by the subunits 30S (16S rRNA, 21 r-proteins) and 50S (5S and 23S rRNAs, 33 r-proteins). The ...Introduction · Processing of pre-mature... · Chemical modification of rRNA...
  52. [52]
    Control of Ribosomal RNA Synthesis by Transcription Factors
    INTRODUCTION. Ribosomal RNAs comprise over 80% of total cellular RNA, and their transcription from rDNA repeats is the most energy intensive transcriptional ...
  53. [53]
    The exosome and RNA quality control in the nucleus - PMC
    The exosome is the main RNA degrader in the nucleus. It was initially identified as a component in the processing and maturation of ribosomal RNA precursors.
  54. [54]
    Degradation of ribosomal RNA precursors by the exosome
    An active system of quality control is best exemplified by the 18S rRNA dimethylase Dim1p. This is required both for rRNA methylation and processing, but these ...
  55. [55]
    Biogenesis of spliceosomal small nuclear ribonucleoproteins - Fischer
    Apr 25, 2011 · Polymerase (pol) II transcription of protein-coding genes generates precursor mRNAs (pre-mRNAs) with immature 5′- and 3′-ends as well as an open ...Introduction · Synthesis Of Snrna · The Cytoplasmic Assembly...
  56. [56]
    Maturation of small nucleolar RNAs: from production to function - PMC
    Oct 5, 2023 · Here, we review the current knowledge on mechanisms of snoRNA maturation, including the different pathways of processing, and the regulatory ...
  57. [57]
    Re-evaluation of the roles of DROSHA, Exportin 5, and DICER in ...
    Mar 14, 2016 · Our study demonstrates an essential role of DROSHA and an important contribution of DICER in the canonical miRNA pathway.
  58. [58]
    Adenosine-to-inosine RNA editing and human disease
    Nov 29, 2013 · (a) ADAR enzymes catalyze the A-to-I hydrolytic deamination reaction, by which an adenosine loses an amine group and is converted to inosine. ( ...
  59. [59]
    Adenosine Deaminase Acting on RNA (ADAR) Enzymes: A Journey ...
    Oct 31, 2023 · The adenosine deaminase acting on RNA (ADAR) enzymes that catalyze the conversion of adenosine to inosine in double-stranded (ds)RNA are evolutionarily ...
  60. [60]
    A-to-I RNA editing occurs at over a hundred million genomic sites ...
    Based on bioinformatic analyses and deep targeted sequencing, we estimate that there are over 100 million human Alu RNA editing sites, located in the majority ...
  61. [61]
    Interplay between A-to-I Editing and Splicing of RNA - PubMed Central
    May 8, 2022 · We review the interconnections between RNA editing and splicing in the context of human cancer. The editing of transcripts may have various effects on splicing.
  62. [62]
    What do editors do? Understanding the physiological functions of A ...
    Jul 1, 2020 · Adenosine-to-inosine (A-to-I) editing is a post-transcriptional modification of RNA which changes its sequence, coding potential and secondary structure.
  63. [63]
    RNA editing by ADAR1 regulates innate and antiviral immune ...
    Oct 17, 2017 · ADAR1-dependent A-to-I editing has recently been recognized as a key process for marking dsRNA as self, therefore, preventing innate immune ...
  64. [64]
    Abnormalities in A-to-I RNA editing patterns in CNS injuries ... - Nature
    Mar 7, 2017 · Alterations of A-to-I editing have been reported in different diseases of the central nervous system such as depression, epilepsy, schizophrenia ...
  65. [65]
    Biological roles of A-to-I editing: implications in innate immunity, cell ...
    Jun 17, 2023 · Several studies have shown that the RNA editing mainly inhibits the dsRNA-sensing pathway, leading to cancer cell immune tolerance [28–31], ...
  66. [66]
    APOBEC-1 MEDIATED RNA EDITING - PMC - NIH
    This review will examine mammalian C to U RNA editing of apolipoproteinB (apoB) RNA and the role of the catalytic deaminase Apobec-1.
  67. [67]
    C-to-U RNA Editing: Mechanisms Leading to Genetic Diversity
    A third target for C-to-U editing, NAT1, was revealed following forced transgenic overexpression of apobec-1 in murine and rabbit hepatocytes (7. 7. Yamanaka ...<|separator|>
  68. [68]
    The apolipoprotein B mRNA editing complex performs a ... - NIH
    The C to U editing of apolipoprotein B (apoB) mRNA is mediated by a minimal complex composed of an RNA-binding cytidine deaminase (APOBEC1) and a complementing ...
  69. [69]
    Genome-wide identification and functional analysis of Apobec-1 ...
    Jun 19, 2014 · C-to-U RNA editing efficiency among the novel 3′ UTR targets ranged from 31 to 84% (Table 2). Together the results (Tables 1 and 2) identify 54 ...
  70. [70]
    The roles of nucleic acid editing in adaptation of zoonotic viruses to ...
    Apr 7, 2023 · The apolipoprotein-B mRNA-editing complex (APOBEC) family is an expansive group of proteins that deaminate cytidines (C) to uridines (U) in RNA ...Nucleic Acid Editing · Adenosine Deaminase Acting... · Ribonucleic Acid...
  71. [71]
    RNA editing enzymes: structure, biological functions and applications
    Mar 16, 2024 · Apobec1 complementation factor (A1CF) and RBM47 interact in tissue-specific regulation of C to U RNA editing in mouse intestine and liver. RNA.A-To-I Rna Editing · Rna Editing In Cancer · Site-Directed Rna Editing
  72. [72]
    The RNA editing enzyme APOBEC1 induces somatic mutations and ...
    We analyze whether expression of APOBEC1 induces a mutator phenotype in vertebrate cells, likely through direct targeting of genomic DNA.
  73. [73]
    From trans-splicing discovery and onwards, trypanosomes lead the ...
    Apr 20, 2022 · Trans-splicing involves the ligation of two independent RNAs: a ~135 nt mini-exon RNA and the protein coding transcript (VSG, for example).
  74. [74]
    Trans-splicing in trypanosomes: machinery and its impact ... - PubMed
    In trypanosomes, all RNAs are processed by the concerted action of trans-splicing and polyadenylation. In trans-splicing, a common spliced leader (SL) is ...Missing: editing | Show results with:editing
  75. [75]
    An RNA ligase essential for RNA editing and survival of ... - PubMed
    RNA editing in trypanosomes occurs by a series of enzymatic steps that are catalyzed by a macromolecular complex. The TbMP52 protein is shown to be a ...
  76. [76]
    Discovery of drug-like inhibitors of an essential RNA-editing ligase ...
    Here, we present drug-like inhibitors of a key enzyme in the editing machinery, RNA-editing ligase 1 (REL1). These inhibitors were identified through a ...
  77. [77]
    Towards a plant model for enigmatic U‐to‐C RNA editing: the ...
    Oct 31, 2019 · Whereas C-to-U RNA editing is present in all major land plant clades, including the liverworts and the mosses, no evidence has ever been found ...Dna/rna Extraction And... · Determination Of Rna Editing... · ResultsMissing: CDARs | Show results with:CDARs
  78. [78]
    New CRISPR platform expands RNA editing capabilities
    Jul 11, 2019 · RESCUE builds on REPAIR, a technology developed by Zhang's team that changes adenine bases into inosine in RNA. RESCUE significantly expands ...
  79. [79]
    Ribozyme-activated mRNA trans-ligation enables large ... - Science
    Nov 14, 2024 · We report that ribozyme cleavage of two separate mRNAs activated their scarless trans-ligation and translation into full-length protein in ...
  80. [80]
    The majority of A-to-I RNA editing is not required for mammalian ...
    Dec 9, 2019 · Physiologically essential A-to-I editing comprises a small subset of the editome, and the majority of editing is dispensable for mammalian homeostasis.
  81. [81]
    Evolutionary Analyses of RNA Editing and Amino Acid Recoding in ...
    Jul 25, 2019 · Overall, RNA editing is rare in mammals. In humans, only about 3% of ... rate ratio in the evolution of mammalian genes. Mol. Biol ...
  82. [82]
    Transient overexpression of exogenous APOBEC3A causes C-to-U ...
    APOBEC3A cytidine deaminase induces site-specific C-to-U RNA editing of hundreds of genes in monocytes exposed to hypoxia and/or interferons and in pro- ...
  83. [83]
    A Review in Research Progress Concerning m6A Methylation and ...
    Apr 25, 2019 · In 1970, m6A was first recognized as an abundant nucleotide modification in eukaryotic messenger RNA (1), by far the most prevalently known of ...
  84. [84]
    Structural Insights into N6-methyladenosine (m6A) Modification in ...
    First discovered in 1974 in mRNA from cancer cells [16], m6A was subsequently detected in large quantities in various viruses [17], [18], [19], yeast [20], [21] ...
  85. [85]
    m6A RNA methylation: from mechanisms to therapeutic potential
    The consensus motif for METTL3/METTL14 is a commonly occurring DRACH (D = A, G or T; R = A or G; H = A, C or U) consensus sequence, but only a fraction of ...
  86. [86]
    YTH Domain: A Family of N6-methyladenosine (m6A) Readers
    m 6 A is recognized by the YT521-B homology (YTH) domain-containing proteins, which subsequently direct different complexes to regulate RNA signaling pathways.
  87. [87]
    The role of m6A modification in the biological functions and diseases
    Feb 21, 2021 · Qi et al. sequenced the N6-methyladenosine (m6A) modified mRNAs in various stages of oocytes in Xenopus laevis, and identified bunch of mRNAs ...Missing: history | Show results with:history
  88. [88]
    FTO m6A Demethylase in Obesity and Cancer - PubMed Central - NIH
    Mar 30, 2022 · Our review aims to confirm m6A demethylation as a risk factor in obesity and provoke new research in FTO and human disorders.
  89. [89]
    Functions and therapeutic applications of pseudouridylation - Nature
    May 20, 2025 · In this Review, we discuss the emerging functions of pseudouridylation in gene regulation, focusing on how pseudouridine in mRNA, tRNA and ribosomal RNA (rRNA) ...Missing: modification paper
  90. [90]
    Pseudouridine in a new era of RNA modifications | Cell Research
    Nov 4, 2014 · When incorporated into RNA, Ψ can alter RNA secondary structure by increasing base stacking, improving base pairing and rigidifying sugar- ...Missing: review | Show results with:review
  91. [91]
    5-methylcytosine promotes mRNA export — NSUN2 as the ... - Nature
    Apr 18, 2017 · 5-methylcytosine (m 5 C) is a post-transcriptional RNA modification identified in both stable and highly abundant tRNAs and rRNAs, and in mRNAs.Missing: review | Show results with:review
  92. [92]
    RNA modifications in cellular metabolism: implications for ... - Nature
    Mar 27, 2024 · These post-transcriptional modifications alter the canonical ribose and base structure to determine RNA fates, including splicing, trafficking, ...
  93. [93]
    Absolute quantitative and base-resolution sequencing reveals ...
    Sep 30, 2024 · Pseudouridine (Ψ) is one of the most abundant modifications in cellular RNA. However, its function remains elusive, mainly due to the lack ...
  94. [94]
    Detection technologies for RNA modifications - Nature
    Oct 21, 2022 · In this review, we summarize the current knowledge about these RNA modification detection technologies and discuss the challenges for the existing detection ...
  95. [95]
    2′-O-methylation (Nm) in RNA: progress, challenges, and future ...
    RNA 2′-O-methylation (Nm) is highly abundant in noncoding RNAs including ribosomal RNA (rRNA), transfer RNA (tRNA), and small nuclear RNA (snRNA).
  96. [96]
    Dual function of C/D box small nucleolar RNAs in rRNA ... - PNAS
    SNORDs are small noncoding RNAs, and their best-understood function is to target the methyltransferase fibrillarin to rRNA.
  97. [97]
    Profiling of 2′-O-Me in human rRNA reveals a subset of fractionally ...
    Jun 1, 2016 · This study constitutes the first comprehensive mapping of 2′-O-Me sites in human rRNA using a high throughput sequencing approach.
  98. [98]
    2′-O-Methylation of Ribosomal RNA: Towards an Epitranscriptomic ...
    Oct 3, 2018 · 2′-O-Methylation protects RNA from hydrolysis and modifies RNA strand flexibility but does not contribute to Watson-Crick base pairing.
  99. [99]
    Phosphorothioates, Essential Components of Therapeutic ...
    This review will focus on the impact of the phosphorothioate group in oligonucleotides, which renders them suitable for therapeutic applications. This backbone ...